6.3.1. treatment low-risk disease. 6.3.1.1. active surveillance main risk men low-risk disease over-treatment (see sections 6.1.1, 6.2.1); therefore considered soc patients life expectancy > ten years based comorbidities age) curative treatment would considered case disease progression. 6.3.1.1.1. active surveillance - inclusion criteria guidance regarding selection criteria limited lack data prospective rcts. consequence, panel undertook international collaborative study involving healthcare practitioners patients develop consensus statements deferred treatment curative intent localised pca, covering domains (detective study) , well formal sr various protocols . criteria often published include: isup grade group 1, clinical stage ct1c ct2a, psa < 10 ng/ml psa-d < 0.15 ng/ml/cc, based systematic biopsy schemes . latter threshold remains controversial . criteria supported detective study consensus. agreement maximum number systematic cores involved cancer maximum percentage core involvement (ci), although recognition extensive disease mri exclude men as, even though firm definition this, especially targeted biopsies confirm isup grade group 1 . sr meta-analysis found three clinico-pathological variables significantly associated reclassification, high psa-d, > 2 positive cores (on systematic biopsies) african-american descent . addition, previous pathology consensus group suggested excluding men following features present: predominant ductal carcinoma (including pure idc), cribriform histology, sarcomatoid carcinoma, small cell carcinoma, epe lvi needle biopsy perineural invasion . multi-disciplinary consensus conference germline testing attempted develop genetic implementation framework management pca . based consensus, brca2-gene testing recommended discussions could performed men family history prostate, breast ovarian cancers. however, nature discussions positive result influences management beyond scope project. currently, brca2 mutation exclude patient tumour factors otherwise favourable. furthermore, included programmes, patients known brca2 mutation cautiously monitored time robust data available. 6.3.1.1.2. tissue-based prognostic biomarker testing selection active surveillance biomarkers, including oncotype dx®, prolaris®, decipher®, portos promark® promising (see section 5.2.8.3). however, data needed markers used standard clinical practice . 6.3.1.1.3. magnetic resonance imaging selection active surveillance men eligible based upon systematic biopsy findings alone pre-biopsy mri, re-biopsy within 6–12 months (usually referred ‘confirmatory biopsy’) seems mandatory exclude sampling error. large body literature including two rcts showed adding mri-targeted biopsy systematic sampling confirmatory biopsy improved detection isup grade ≥ 2 cancers thus, patient selection [121,499,500,502-504]. adding mri-targeted biopsy systematic sampling confirmatory biopsy improved upgrade detection increments 0-7.9 per 100 men depending series . meta-analysis 6 studies, rate upgrading isup grade group ≥ 2 cancer increased 20% (95% ci: 16–25%) 27% (95% ci: 22–34%) mri-targeted biopsy added systematic biopsy . active surveillance mri study (asist) randomised men scheduled confirmatory biopsy either 12-core systematic biopsy mri targeted biopsy (when indicated), combined systematic biopsy (up 12 cores total). two yearsof follow-up, use mri confirmatory biopsy resulted fewer failures surveillance (19% vs. 35%, p = 0.017) fewer patients progressing isup grade group ≥ 2 cancer (9.9% vs. 23%, p = 0.048) . however, systematic biopsy retains additional value, argues combined biopsy approach . detective study agreed men eligible combined systematic- mri-targeted biopsy require confirmatory biopsy . pca diagnosis made mri-targeted biopsy alone (recommended countries national guidelines, e.g., nordic countries order lower risk over-detection insignificant tumours, confirmative systematic biopsy performed definite decision rule widespread cancer growth prostate. 6.3.1.1.4. follow-up active surveillance based detective consensus study, follow-up strategy based serial dre (at least yearly), psa (at least once, every six months) repeated biopsy. also agreed psa progression change psa kinetics alone lead reclassification accompanied changes histology repeat biopsy . yerram et al., analysed prospectively-maintained cohort 369 patients (272 isup grade group 1 cancer 97 isup grade group 2 cancer) selected combined systematic mri-targeted sampling confirmatory biopy. two years, systematic biopsy, mri-targeted biopsy combined biopsy detected grade progression 44 patients (15.9%), 73 patients (26.4%) 90 patients (32.5%), respectively. suggests biopsy approaches retain added value, confirmatory biopsy, also . 2016, prostate cancer radiological estimation change sequential evaluation (precise) criteria established standardise assessment tumour progression serial mri . progression mri, defined using precise criteria, not, strong predictor histological upgrading . two independent meta-analyses assessed value mri progression criteria predicting histological progression (mostly defined progression isup grade group ≥ 2). pooled histological progression rate 27% reviews. biopsies triggered mri progression findings, approximately two thirds biopsies would avoided, cost missing 40% men histological progression. addition, least half biopsied men would negative findings histological progression thus would undergone unnecessary biopsies. histological progression restricted progression isup grade group > 3, approximately 30% histological progression would missed approximately 80% biopsies performed would unnecessary. use precise criteria seem change results . supports maintaining protocol-mandated follow-up biopsies course as. however, several factors found associated low re-classification rates long pfs; negative baseline follow-up mri [505,512-518], low psa-d , low psa velocity negative biopsy (i.e., cancer all) confirmatory follow-up biopsy . patients stable (precise 3) follow-up mri, low psa-d may associated low rate progression . using criteria, might possible, future, create risk-based personalised biopsy schedules. panel sr incorporating 263 surveillance protocols showed 78.7% protocols mandated per-protocol confirmatory biopsies within first two yearsand 57.7% protocols performed repeat biopsy least every three years ten years start . another review concluded negative follow-up biopsy associated 50% decrease risk future reclassification upgrading . single-centre cohort 514 patients underwent least three protocol-mandated biopsies diagnosis (the confirmatory biopsy least two additional surveillance biopsies), men one negative biopsy (i.e., cancer all) confirmatory second biopsy, men two consecutive negative biopsies lower likelihood positive third biopsy significantly better 10-year treatmentfree survival . suggests men repetitive negative biopsies may pursue least less frequent untriggered biopsies. 6.3.1.1.5. active surveillance - change treatment men may remain whilst continue consent, life expectancy > ten years disease remains indolent. patient anxiety continued surveillance occurs around 10% patients recognised valid reason active treatment . thorough discussion pros/cons vs. active treatment already time diagnosis therefore outmost importance. common development comorbidities may result decision transfer ww strategy. psa change alone (including psa-dt < 3 years) change management based weak link grade progression rather trigger investigation. clear agreement detective consensus meeting change psa lead repeat-mri repeat-biopsy. also agreed changes follow-up mri needed confirmatory biopsy considering active treatment . however, histopathology criteria required trigger change management targeted biopsy era remain debated. magnetic resonance imaging-targeted biopsy induces grade shift isup grade group 2–3 cancers detected mri-targeted biopsy have, average, better prognosis detected systematic sampling (see section 5.2.4.2.6.4). increasing number men favourable intermediate-risk disease managed (see section 6.2.2.1), seems illogical use progression isup grade group 2 based targeted biopsies sole criterion reclassification. addition, acknowledged detective consensus meeting, number positive cores indicator tumour volume anymore targeted biopsies performed . agreement could reached pathological criteria required trigger change management detective consensus meeting . however, based findings sr incorporating 271 reclassification protocols, patients low-volume isup grade group 2 disease recruitment, increased systematic core positivity (> 3 cores involvement [> 50% per core]) repeat systematic biopsies using mri, reclassified . 6.3.1.2. alternatives active surveillance patients life expectancy < ten years (based comorbidities age), curative treatment would option case progression, ww soc rather as. terms alternatives management patients low-risk disease data randomised studies. pivot trial (section 6.1.1) compared surgery vs. observation, 42% patients low-risk disease . sub-group analysis revealed low-risk disease statistically significant difference all-cause mortality surgery vs. observation (rr: 0.93, 95% ci: 0.78–1.11). protect study (section 6.1.1) compared less organised strategy “active monitoring” (i.e. repeat psa management only) vs. surgery vs. ebrt, 66% patients d’amico low-risk disease . study found, 15 years follow-up, difference three arms terms os css, higher metastatic progression (9.4%) compared surgery (4.7%) ebrt (5.0%). robust data comparing contemporary protocols either surgery ebrt patients low-risk disease. active surveillance considered soc patients low- intermediate risk disease life expectancy > ten years. surgery ebrt considered alternatives patients suitable treatments thorough information pros cons active treatment, information refuse reason deemed unfit as, accept trade-off toxicity prevention disease progression. treatments whole-gland ablative therapy (e.g. cryotherapy hifu) focal ablative therapy remain unproven setting localised low-risk disease compared radical treatment options used outside trial setting well-designed prospective cohort setting. treatments discussed detail section 6.1.5. 6.3.1.2.1. androgen deprivation monotherapy data regarding use adt monotherapy men low-risk localised disease may inferred indirectly early prostate cancer (epc) trial programme published findings 2006 . epc programme comprises three large rcts including 8,113 men localised (ct1–2, n0/nxm0) locally advanced (ct3–4, n; t, n+, m0) pca. intervention oral bicalutamide 150 mg monotherapy vs. placebo following standard care (defined rp, radical ebrt ww). primary endpoints pfs os. patients stratified according clinical stage only; data regarding psa gs assessed. authors found patients localised disease, adt monotherapy improve pfs os subgroups, compared placebo. instead, statistically insignificant numerical trend towards worse os adt ww sub-group (hr: 1.16, 95% ci: 0.99–1.37; p = 0.07). although trial directly address men low-risk disease, offered evidence suggesting otherwise asymptomatic men localised disease receive adt monotherapy. phase 2 rct addressed similar approach, patients randomised enzalutamide plus alone. study indicated psa progression could delayed, odds negative biopsy increased median follow-up time 1.3 years, patients side effects treatment without showing long-term benefits treatment . hence, evidence supporting use hormonal treatment asymptomatic men low-risk disease eligible local/radical treatment; men simply offered ww alone. 6.3.1.3. summary evidence guidelines management low-risk disease* summary evidenceleww soc, based life expectancy.2aall active treatment options present risk over-treatment.1a recommendationsstrength ratingwatchful waitingmanage patients life expectancy < ten years watchful waiting.strongactive surveillance (as)manage patients life expectancy > ten years low-risk disease as.strongselection patientspatients cribriform intraductal histology biopsy excluded as.strongperform magnetic resonance imaging (mri) confirmatory biopsy mri performed initial biopsy.strongtake targeted biopsy (of pi-rads ≥ 3 lesion) systematic biopsy confirmatory biopsy performed.strongif mri available, per-protocol confirmatory prostate biopsies performed.weakif patient upfront mri followed systematic targeted biopsies need confirmatory biopsies.weakstrategy surveillancerepeat biopsies performed least every three years ten years.weakin case prostate-specific antigen progression change digital-rectal exam-ination mri findings, progress active treatment without repeat biopsy.strong